Literature DB >> 6195967

Post-translational heterogeneity of the human vitamin D-binding protein (group-specific component).

D H Coppenhaver, N P Sollenne, B H Bowman.   

Abstract

The vitamin D-binding protein in human serum (the group-specific component) is an alpha 2-globulin which is genetically polymorphic in all populations studied. Previous work (J. Svasti and B. H. Bowman (1978) J. Biol. Chem. 253, 5188-5194, and J. Svasti, A. Kurosky, A. Bennett, and B. H. Bowman (1979) Biochemistry 18, 1611-1617) has shown that the electrophoretic variations of the proteins controlled by two allelic genes, Gc1 and Gc2, are due to at least three amino acid substitutions between Gc1 and Gc2 (Svasti et al. (1979] and to heterogeneity in the Gc1 phenotype arising from carbohydrate dissimilarities. Gc1 migrates electrophoretically as two protein bands, while Gc2 migrates cathodally as a single band. This study demonstrates a post-translational glycosylation difference occurring in a single area of the Gc1 sequence which accounts for the heterogeneity observed previously. The glycosylation site, a threonine residue, appears to be in a sequence which differs between Gc1 and Gc2. The O-glycosidic bond, which is typical of mucins, is rare in plasma proteins. The cyanogen bromide fragment containing the galactosamine-containing carbohydrate in Gc1 was partially sequenced through 20 residues from the amino terminus. No detectable galactosamine could be found in the homologous cyanogen bromide fragment in Gc2. A new purification procedure for the vitamin D-binding protein in human plasma has been developed. Three chromatographic steps provide purified protein.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6195967     DOI: 10.1016/0003-9861(83)90287-4

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  9 in total

1.  Evolutionary and structural relationships among the group-specific component, albumin and alpha-fetoprotein.

Authors:  F Yang; V J Luna; R D McAnelly; K H Naberhaus; R L Cupples; B H Bowman
Journal:  Nucleic Acids Res       Date:  1985-11-25       Impact factor: 16.971

2.  A defect in inducible beta-galactosidase of B lymphocytes in the osteopetrotic (mi/mi) mouse.

Authors:  N Yamamoto; V R Naraparaju
Journal:  Immunology       Date:  1996-08       Impact factor: 7.397

3.  Participation of serum proteins in the inflammation-primed activation of macrophages.

Authors:  N Yamamoto; N P Willett; D D Lindsay
Journal:  Inflammation       Date:  1994-06       Impact factor: 4.092

4.  Vitamin D3 binding protein required for in vitro activation of macrophages after alkylglycerol treatment of mouse peritoneal cells.

Authors:  N Yamamoto; S Homma; J G Haddad; M A Kowalski
Journal:  Immunology       Date:  1991-11       Impact factor: 7.397

5.  Regulation of inflammation-primed activation of macrophages by two serum factors, vitamin D3-binding protein and albumin.

Authors:  N Yamamoto; R Kumashiro; M Yamamoto; N P Willett; D D Lindsay
Journal:  Infect Immun       Date:  1993-12       Impact factor: 3.441

6.  Human group-specific component (Gc) is a member of the albumin family.

Authors:  F Yang; J L Brune; S L Naylor; R L Cupples; K H Naberhaus; B H Bowman
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

7.  Glycosylation status of vitamin D binding protein in cancer patients.

Authors:  Douglas S Rehder; Randall W Nelson; Chad R Borges
Journal:  Protein Sci       Date:  2009-10       Impact factor: 6.725

8.  Vitamin D3 binding protein (group-specific component) is a precursor for the macrophage-activating signal factor from lysophosphatidylcholine-treated lymphocytes.

Authors:  N Yamamoto; S Homma
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-01       Impact factor: 11.205

9.  Vitamin D in Type 2 Diabetes: Genetic Susceptibility and the Response to Supplementation.

Authors:  Edith Klahold; Marissa Penna-Martinez; Franziska Bruns; Christian Seidl; Sabine Wicker; Klaus Badenhoop
Journal:  Horm Metab Res       Date:  2020-06-15       Impact factor: 2.936

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.